Shares of Orexigen (OREX +16.7%) are soaring after Credit Suisse initiates coverage with an...

|About: Orexigen Therapeutics, Inc. (OREX)|By:, SA News Editor

Shares of Orexigen (OREX +16.7%) are soaring after Credit Suisse initiates coverage with an Outperform, saying it likes the prospects of a trial that will look at the cardiovascular impact of Contrave. Leerink Swann also recommends investors buy it aggressively. Meanwhile, it starts Arena Pharmaceutical (ARNA -4.6%) with an Underperform , saying Belviq may not generate enough revenue to justify the stock's current valuation.